Elecsys tsh

Manufactured by Roche

Sourced in Switzerland

The Elecsys TSH is a laboratory equipment product manufactured by Roche. It is used to measure the levels of thyroid-stimulating hormone (TSH) in patient samples. The Elecsys TSH provides a quantitative determination of TSH concentration, which is a key indicator of thyroid function.

Automatically generated - may contain errors

Lab products found in correlation

Elecsys t3, by Roche (1 mentions) Elecsys t4, by Roche (1 mentions) Eclusys ft4, by Roche (1 mentions) Elecsys ft3iii, by Roche (1 mentions) Elecsys ft4iii, by Roche (1 mentions)

Close spelling variants of this product

Elecsys FT4 III and TSH kits Elecsys® TSH assay Elecsys TSH kit

4 protocols using elecsys tsh

Thyroid Function in Nephrotic Syndrome

Check if the same lab product or an alternative is used in the 5 most similar protocols

The medical records of the patients were retrospectively reviewed. For 31 patients who were diagnosed with NS, serum total protein, albumin, total cholesterol, electrolyte levels, Cr, and estimated glomerular filtration ratio (eGFR) were measured. In addition, thyroid hormone profiles were analyzed. The total 24-hour urinary protein excretion, or early-morning spot urinary protein/Cr ratio was measured.
The serum T3, T4, TSH, and free T4 levels were measured using the electro-chemiluminescence immunoassay (ECLIA) to assess the thyroid function. In the ECLIA, chemiluminescent ruthenium is used to electrically induce antigen-antibody reactions on the surface of steroptoavidin-coated paramagnetic micro-beads, and the luminescence emitted is measured to determine the concentration of the substance of interest. The Elecsys T3, Elecsys T4, Elecsys TSH, and Elecsys FT4 II kits from Roche Diagnostics Co., Ltd. were used. For the normal reference range, the normal range of each kit was used (range corresponding to the 2.5th–97.5th percentiles).
In addition, anti-thyroglobulin, anti-thyroid-stimulating hormone receptor antibody, and anti-thyroid peroxidase antibodies were measured in some patients with overt hypothyroidism.

Jung S.H., Lee J.E, & Chung W.Y. (2018). Changes in the thyroid hormone profiles in children with nephrotic syndrome. Korean Journal of Pediatrics, 62(3), 85-89.

+ Open protocol

+ Expand

Diagnostic Criteria for Graves' and Painless Thyroiditis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The primary outcome was GD, and the diagnosis of GD was made on the basis of an elevated serum FT3 level and FT4 level, suppression of the serum TSH level, a typical goiter, ophthalmopathy, the presence of thyroid stimulating antibody, and increased RAIU. The diagnosis of PT was made on the basis of an elevated serum FT3 level and FT4 level, suppression of the serum TSH level, negative TRAb, and decreased RAIU. FT3 and FT4 levels were measured by electrochemiluminescence immunoassays (ECLIAs) (Elecsys FT3 and ECLusys FT4, Roche Diagnostics GmbH, Basel, Switzerland; manufacturer's reference limits: 2.2-4.3 pg/mL and 0.8-1.6 ng/dL respectively). The TSH level was measured by an ECLIA (Elecsys TSH; Roche Diagnostics GmbH, Basel, Switzerland; manufacturer's reference limits: 0.2-4.5 mIU/L). Control subjects (without any thyroid diseases) were identified on the basis of normal thyroid function, i.e., FT3, FT4, and TSH levels within their reference ranges, negative test for any of the thyroid autoantibodies, homogeneous echo pattern on thyroid images, i.e., absence of thyroid nodules, and absence of goiter.

Yoshihara A., Yoshimura Noh J., Inoue K., Taguchi J., Hata K., Aizawa T., Taira Arai Y., Watanabe N., Fukushita M., Matsumoto M., Suzuki N., Hoshiyama A., Suzuki A., Mitsumatsu T., Kinoshita A., Mikura K., Yoshimura R., Sugino K, & Ito K. (2022). Prediction model of Graves' disease in general clinical practice based on complete blood count and biochemistry profile. Endocrine journal, 69(9).

+ Open protocol

+ Expand

Graves' Disease Diagnostic Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

TSH, FT4, and FT3 were measured employing AxSYM TSH, FT4, and FT3 assays (Dainabot Co., Tokyo, Japan), respectively, at the diagnosis of Graves' disease in some patients. In the other patients, TSH, FT4, and FT3 were measured employing ARCHITECT TSH, FT4, and FT3 assays (Abbott Co., Tokyo, Japan), respectively, at the diagnosis of Graves' disease.
On re-exposure to MMI, TSH and FT4 were measured with Elecsys TSH and FT4 assays (Roche Diagnostics GmbH, Mannheim, Germany), respectively. TRAb was measured with a TSH receptor antibody assay (RSR Ltd., Cardiff, UK) or with a Elecsys TRAb assay (Roche Diagnostics GmbH). Normal ranges are described in Table.

, & Kubota S. (2016). Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU). Internal Medicine, 55(22), 3235-3237.

+ Open protocol

+ Expand

Thyroid Hormone Levels in Liver Disease

Check if the same lab product or an alternative is used in the 5 most similar protocols

All laboratory tests were conducted at the ISO-certified Department of Laboratory Medicine of the Vienna General Hospital. Blood withdrawals were conducted in a standardized manner after HVPG measurement under fasting conditions and after resting in the supine position for at least 30 min. Serum levels of TSH (normal range 0.27–4.2 μIU/ml; Elecsys TSH, Roche Diagnostics, Mannheim, Germany), as well as fT4 (normal range 0.76–1.66 ng/dl; Elecsys fT4 III, Roche Diagnostics, Mannheim, Germany) and fT3 (normal range 2.15–4.12 pg/ml; Elecsys fT3 III, Roche Diagnostics) were analyzed by electrochemoluminescence immunoassay (Roche Diagnostics). Standard laboratory methods were used for the assessment of routine laboratory parameters. Low fT4 and low fT3 were defined as fT4 upper limit of normal (ULN).

Hartl L., Simbrunner B., Jachs M., Wolf P., Bauer D.J., Scheiner B., Balcar L., Semmler G., Schwarz M., Marculescu R., Dannenberg V., Trauner M., Mandorfer M, & Reiberger T. (2023). Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortality. JHEP Reports, 6(1), 100954.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!